Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813385 | 0.91 | CHEK1 (0.40) | KCNJ1CHEK1KDRPDGFRBCYP2A6 | |
| SCHEMBL4813873 | 0.75 | KDR (0.60) | CHEK1KDRPDGFRBCDK1CDK2 | |
| SCHEMBL4811071 | 0.73 | KDR (0.61) | CHEK1KDRPDGFRBCDK1CDK2 | |
| SCHEMBL4812439 | 0.72 | CHEK1 (0.65) | CHEK1PDGFRBEIF2AK1 | |
| SCHEMBL4817877 | 0.72 | LTK (0.60) | KCNJ1CHEK1KDRCDK1CDK2 | |
| SCHEMBL4815668 | 0.71 | PDGFRB (0.61) | CHEK1PDGFRBEIF2AK1 | |
| SCHEMBL4809861 | 0.70 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL4809204 | 0.70 | CHEK1 (0.67) | CHEK1KDREIF2AK1 | |
| SCHEMBL7090179 | 0.67 | KDR (0.72) | CHEK1KDRPDGFRBCDK1CDK2 | |
| SCHEMBL4810779 | 0.66 | CHEK1 (0.55) | CHEK1PDGFRBEIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KCNJ1 3275/4885CHEK1 79/4885KDR 666/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | KCNJ1 2258/4885CHEK1 73/4885KDR 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.